Interpace Biosciences, Inc.
IDXG
$1.98
-$0.01-0.50%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -17.47% | -6.06% | 9.78% | 19.50% | 17.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -17.47% | -6.06% | 9.78% | 19.50% | 17.21% |
| Cost of Revenue | -14.13% | 3.98% | 13.00% | 15.20% | 13.49% |
| Gross Profit | -19.37% | -11.31% | 7.95% | 22.04% | 19.44% |
| SG&A Expenses | -11.53% | 3.00% | 13.66% | 8.21% | 7.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.56% | 3.45% | 12.87% | 9.60% | 7.61% |
| Operating Income | -41.01% | -46.39% | -7.72% | 100.43% | 104.59% |
| Income Before Tax | -45.70% | -42.02% | 1.65% | 196.88% | 204.69% |
| Income Tax Expenses | -530,350.00% | -105.88% | -17.65% | 5.88% | -76.47% |
| Earnings from Continuing Operations | 259.69% | -41.87% | 1.72% | 198.11% | 206.80% |
| Earnings from Discontinued Operations | -67.62% | -61.08% | -48.15% | 26.27% | 21.29% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 266.68% | -44.65% | -0.20% | 230.64% | 242.99% |
| EBIT | -41.01% | -46.39% | -7.72% | 100.43% | 104.59% |
| EBITDA | -38.06% | -43.51% | -8.04% | 78.88% | 68.53% |
| EPS Basic | 290.28% | -51.95% | -11.18% | 206.98% | 215.07% |
| Normalized Basic EPS | -36.17% | -42.71% | 0.54% | 192.50% | 199.52% |
| EPS Diluted | -46.12% | -82.81% | -41.09% | 148.21% | 216.42% |
| Normalized Diluted EPS | -94.95% | -98.95% | -65.28% | 74.67% | 126.00% |
| Average Basic Shares Outstanding | 0.85% | 1.17% | 1.42% | 1.53% | 1.61% |
| Average Diluted Shares Outstanding | 39.08% | 524.26% | 394.58% | 396.87% | 264.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |